Collectively, these results support the hypothesis that a combination regimen in chronic hepatitis B and C may be of therapeutic efficacy, with Tα1 likely promoting the optimal conditions for the full exploitation of the biological effects of IFNα. This evidence concerns the gene TAAR1 and chronic hepatitis B virus infection.